{"log_id": 2841220018213565722, "direction": 0, "words_result_num": 44, "words_result": [{"probability": {"variance": 0.004943, "average": 0.97147, "min": 0.672974}, "location": {"width": 335, "top": 344, "height": 31, "left": 493}, "words": "500mg121025±4222.3±1"}, {"probability": {"variance": 0.00332, "average": 0.961295, "min": 0.808403}, "location": {"width": 157, "top": 347, "height": 25, "left": 959}, "words": "5289.03±3.92"}, {"probability": {"variance": 0.000584, "average": 0.973864, "min": 0.949706}, "location": {"width": 25, "top": 395, "height": 22, "left": 500}, "words": "75"}, {"probability": {"variance": 0.00697, "average": 0.958482, "min": 0.686763}, "location": {"width": 223, "top": 392, "height": 25, "left": 600}, "words": "12785±3422.24"}, {"probability": {"variance": 0.000767, "average": 0.975419, "min": 0.91825}, "location": {"width": 77, "top": 397, "height": 22, "left": 1041}, "words": "38±3.80"}, {"probability": {"variance": 0.001792, "average": 0.986903, "min": 0.724211}, "location": {"width": 1089, "top": 436, "height": 38, "left": 287}, "words": "转移性实体瘤患者餐后单次空腹口服500mg,750mg和850mg后,吸收略有延迟,原形药"}, {"probability": {"variance": 0.015557, "average": 0.933567, "min": 0.472124}, "location": {"width": 1133, "top": 484, "height": 38, "left": 239}, "words": "物血浆浓度平均达峰时间约为3.9-5.1h,平均消除半衰期为8.5-9.0。在50mg和750mg剂"}, {"probability": {"variance": 0.008079, "average": 0.968545, "min": 0.402759}, "location": {"width": 1135, "top": 530, "height": 41, "left": 239}, "words": "量组,原形药物血浆暴露量(AUC和Cmx)与剂量成正比例,但850mg剂量组原形药暴露量"}, {"probability": {"variance": 0.000295, "average": 0.994226, "min": 0.910118}, "location": {"width": 712, "top": 577, "height": 36, "left": 242}, "words": "水平增加比例低于剂量增加比例。各药代动力学参数见表6"}, {"probability": {"variance": 0.000841, "average": 0.981064, "min": 0.86938}, "location": {"width": 982, "top": 628, "height": 34, "left": 285}, "words": "表6.转移性实体瘤患者单次空腹口服500mg、750mg和850mg阿帕替尼后的药代动力学分析"}, {"probability": {"variance": 0.01079, "average": 0.896126, "min": 0.792253}, "location": {"width": 86, "top": 680, "height": 29, "left": 922}, "words": " AUCOA&"}, {"probability": {"variance": 0.024581, "average": 0.830296, "min": 0.673514}, "location": {"width": 54, "top": 701, "height": 29, "left": 461}, "words": "剂量"}, {"probability": {"variance": 0.031722, "average": 0.78931, "min": 0.564425}, "location": {"width": 82, "top": 703, "height": 27, "left": 774}, "words": " Tmx(h"}, {"probability": {"variance": 0, "average": 0.915651, "min": 0.915651}, "location": {"width": 20, "top": 733, "height": 20, "left": 959}, "words": "h"}, {"probability": {"variance": 0.004422, "average": 0.959787, "min": 0.799014}, "location": {"width": 95, "top": 774, "height": 29, "left": 774}, "words": "392±1.55"}, {"probability": {"variance": 0.053227, "average": 0.665521, "min": 0.43481}, "location": {"width": 22, "top": 776, "height": 25, "left": 1000}, "words": "5"}, {"probability": {"variance": 0.001768, "average": 0.923263, "min": 0.856306}, "location": {"width": 54, "top": 776, "height": 25, "left": 1107}, "words": "上249"}, {"probability": {"variance": 0.00497, "average": 0.975299, "min": 0.592077}, "location": {"width": 525, "top": 822, "height": 27, "left": 637}, "words": "1122±5912.78±0.639895±55369.07±1.29"}, {"probability": {"variance": 0.006332, "average": 0.888424, "min": 0.759306}, "location": {"width": 52, "top": 870, "height": 25, "left": 692}, "words": "2468"}, {"probability": {"variance": 0.001266, "average": 0.956814, "min": 0.892312}, "location": {"width": 73, "top": 870, "height": 22, "left": 1060}, "words": "8.99±2"}, {"probability": {"variance": 0.008615, "average": 0.972727, "min": 0.405706}, "location": {"width": 1076, "top": 906, "height": 41, "left": 296}, "words": "在11例转移性实体肿瘤患者考察了750mg/日多次给药的药代动力学特征结果表明在连续"}, {"probability": {"variance": 7.9e-05, "average": 0.995248, "min": 0.95799}, "location": {"width": 660, "top": 952, "height": 38, "left": 239}, "words": "给药期间(56天),受试者体内未发生药物蓄积现象"}, {"probability": {"variance": 0.007951, "average": 0.970919, "min": 0.435184}, "location": {"width": 1055, "top": 1005, "height": 36, "left": 294}, "words": "在转移性实体患者(n=9,男性6名,女性3名)中考察了进食对阿帕替尼吸收的影响,"}, {"probability": {"variance": 0.002229, "average": 0.980669, "min": 0.72495}, "location": {"width": 1130, "top": 1050, "height": 36, "left": 239}, "words": "对受试者餐前1h与餐后0.5h单次口服750mg日吸收的差异进行比较。结果表明进食与服药顺"}, {"probability": {"variance": 0.018296, "average": 0.896346, "min": 0.663843}, "location": {"width": 82, "top": 1096, "height": 29, "left": 239}, "words": "序对Th"}, {"probability": {"variance": 0, "average": 0.715296, "min": 0.715296}, "location": {"width": 38, "top": 1103, "height": 22, "left": 390}, "words": " cm"}, {"probability": {"variance": 0.004206, "average": 0.966065, "min": 0.792734}, "location": {"width": 280, "top": 1096, "height": 34, "left": 502}, "words": "4UC和t均无显著影响"}, {"probability": {"variance": 0.001115, "average": 0.987939, "min": 0.791455}, "location": {"width": 1066, "top": 1142, "height": 36, "left": 296}, "words": "在转移性实体瘤患者单次口服给药的研究中观察到850mg剂量组不同性别受试者阿帕替"}, {"probability": {"variance": 0.007372, "average": 0.974018, "min": 0.441134}, "location": {"width": 1114, "top": 1187, "height": 36, "left": 239}, "words": "尼及其代谢产物M1暴露水平(Cm和AUC)存在统计学差异,其中女性AUC比男性的高1.96"}, {"probability": {"variance": 0.002001, "average": 0.977036, "min": 0.814804}, "location": {"width": 1046, "top": 1233, "height": 38, "left": 239}, "words": "倍,C高3.57倍。:由于样本量较小(男性5例,女性4例),尚难对这种差别作出结论"}, {"probability": {"variance": 0.00092, "average": 0.987869, "min": 0.864642}, "location": {"width": 1078, "top": 1279, "height": 38, "left": 294}, "words": "年龄、体重对阿帕替尼的药代动力学特征无显著影响,因此临床使用时不需根据上述因素"}, {"probability": {"variance": 2e-06, "average": 0.998262, "min": 0.995901}, "location": {"width": 196, "top": 1329, "height": 31, "left": 239}, "words": "对剂量进行调整"}, {"probability": {"variance": 0.00866, "average": 0.963095, "min": 0.660004}, "location": {"width": 342, "top": 1370, "height": 38, "left": 294}, "words": "剂量水平与暴露水平相关性"}, {"probability": {"variance": 0.009467, "average": 0.971149, "min": 0.453174}, "location": {"width": 1078, "top": 1418, "height": 36, "left": 294}, "words": "转移性实体瘤患者单次给药的药代动力学研究中,阿帕替尼的暴露水平随着口服给药剂量"}, {"probability": {"variance": 0.015907, "average": 0.950719, "min": 0.49092}, "location": {"width": 424, "top": 1466, "height": 36, "left": 239}, "words": "增加而增加,但不呈剂量比例关系"}, {"probability": {"variance": 0.00943, "average": 0.929166, "min": 0.762771}, "location": {"width": 114, "top": 1512, "height": 34, "left": 292}, "words": "不同瘤种"}, {"probability": {"variance": 0.00591, "average": 0.972537, "min": 0.545769}, "location": {"width": 1076, "top": 1558, "height": 34, "left": 294}, "words": "在Ⅱ期研究中分别考察了在晚期结直肠癌患者(n=40)和晚期胃癌患者(n=12)的药代动力"}, {"probability": {"variance": 0.006053, "average": 0.971489, "min": 0.554768}, "location": {"width": 1128, "top": 1603, "height": 36, "left": 242}, "words": "学特征。晚期结直肠癌患者与同等剂量下健康受试者药代参数相似,而胃癌患者吸收延迟,暴"}, {"probability": {"variance": 0.000711, "average": 0.983749, "min": 0.890901}, "location": {"width": 1130, "top": 1649, "height": 36, "left": 239}, "words": "露水平更低。晚期胃癌患者对原发病灶的手术治疗(如胃大部切除术)以及体的体质状况可"}, {"probability": {"variance": 1e-05, "average": 0.998159, "min": 0.987558}, "location": {"width": 365, "top": 1699, "height": 34, "left": 242}, "words": "能会影响药物的的溶解和吸收"}, {"probability": {"variance": 0, "average": 0.999438, "min": 0.998883}, "location": {"width": 59, "top": 1747, "height": 29, "left": 299}, "words": "分布"}, {"probability": {"variance": 0.000229, "average": 0.992781, "min": 0.933491}, "location": {"width": 1076, "top": 1788, "height": 36, "left": 296}, "words": "健康受试者单次空腹口服250mg,500mg和750mg甲磺酸阿帕替尼片后,平均表观分布容"}, {"probability": {"variance": 0.004737, "average": 0.966593, "min": 0.629059}, "location": {"width": 1053, "top": 1836, "height": 38, "left": 239}, "words": "积为929~2165L用超滤法测得阿帕替尼血浆浓度在200ng/ml时的血浆蛋白结合率>86%"}, {"probability": {"variance": 0, "average": 0.999621, "min": 0.999348}, "location": {"width": 59, "top": 1887, "height": 31, "left": 301}, "words": "代谢"}], "language": 3}